Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of “Moderate Buy” by Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among […]
More Stories
France’s Far-Left Protests on Halloween Descend Into Violence as Unrest Spreads Across Europe
By Etienne Fauchaire PARIS—Tens of thousands of left-wing demonstrators marched along the eastern edge of Paris on Saturday, in a...
Judge Dismisses Trump’s Defamation Lawsuit Against Wall Street Journal Publisher
By Tom Gantert A federal judge on Oct. 31 dismissed President Donald Trump’s defamation lawsuit against The Wall Street Journal’s...
Cybersecurity Researchers Link North Korea to $6.4 Billion Binance Hack
By Ryan Morgan Private blockchain analysis companies TRM Labs and Chainalysis have both assessed that North Korean state-backed hackers were...
US Approves Possible $2.1 Billion Sale of 500 Patriot Missiles to Ukraine
By Kimberly Hayek The State Department announced Oct. 30 that it has approved a possible sale of 500 Patriot Advanced...
Who is Timothy Busfield? Cases, Movies, Shows, and Wife
After spending several years under the allegation of child abuse charges, a New Mexico judge has finally issued a judgment....
Economic Momentum Builds as New Figures Beat Expectations
By Andrew Morand and Emel Akan The U.S. economy may be doing more than weathering recent shocks. A fresh batch...